Pharmacological investigations of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370). 2. Ulcerogenic effects in rats and dogs.
D000284:Administration, Oral; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000633:toxicity*; D004032:Diet; D004285:Dogs; D004361:Drug Tolerance; D005215:Fasting; D005260:Female; D005947:Glucose; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D008297:Male; D010437:Peptic Ulcer / Q000139:chemically induced*; D010653:Phenylbutazone / Q000633:toxicity; D011708:Pylorus / Q000473:pathology; D011720:Pyrazoles / Q000008:administration & dosage / Q000633:toxicity*; D051381:Rats; D013270:Stomach / Q000473:pathology; D013729:Terpenes / Q000633:toxicity*
D000893:Anti-Inflammatory Agents; D011720:Pyrazoles; D013729:Terpenes; D010653:Phenylbutazone; D005947:Glucose